Diagnostic ECG market to grow by USD 4.35B from 2023-28

The diagnostic electrocardiograph (ECG) market is expected to grow by USD 4.35 billion from 2023 to 2028. In addition, the momentum of the market will progress at a CAGR of 8.49% during the forecast period, according to Technavio Research. The market has been segmented by end-user (hospitals/clinics/cardiac care centers, ambulatory surgical centers, and home settings), product (resting ECG, stress, mobile cardiac telemetry device, and implantable loop recorder), and geography (North America, Europe, Asia, and Rest of World (ROW)).

North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technological advances and new products, a rapidly increasing number of diagnosed ECG tests as well as favorable reimbursement conditions in North America are the major drivers for market growth in this region.

Company profile:
ACS Diagnostics Inc., Allengers Medical Systems Ltd., Ambu AS, Baxter International Inc., Bionet America, BPL MEDICAL TECHNOLOGIES Pvt. Ltd., Cardioline SpA, EDAN Instruments Inc., Fukuda Denshi Co. Ltd., General Electric Co., Innomed Medical Inc., Koninklijke Philips N.V., Midmark Corp., Mindray Bio medical Electronics Co. Ltd., NEXUS LIFECARE PVT. LTD., Nihon Kohden Corp., Norav Medical, OSI Systems Inc., SCHILLER AG, and VectraCor Inc.

ACS Diagnostics Inc. – The company offers diagnostic electrocardiographs such as ACS Diagnostics. Technavio